Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells.
A gene therapy model has been designed to induce tolerance to multiple epitopes expressed in-frame on a soluble IgG fusion protein scaffold. Tolerance to the lambda repressor cI sequence p1-102 or its immunodominant epitopes (p12-26, p73-88) can be elicited when bone marrow (BM) or LPS blasts are transduced and injected into naive or even primed recipients. To explore the mechanism of tolerance, class II(-/-) (knockout, KO) BM cells were transduced with p1-102-IgG and transferred to irradiated recipients. These cells failed to induce tolerance to challenge with p1-102 epitopes, whereas transduced +/+ BM cells did. This supports the importance of class II MHC on the tolerogenic APC rather than secretion and representation in tolerogenesis. When BM cells from muMT KO mice were transfected with p12-26-IgG and injected into irradiated mice, these transduced BM cells also failed to induce tolerance to an immunodominant epitope. These results suggest the direct involvement of B cells in tolerance to p1-102 epitopes. IL-10 KO BM cells infected with a p12-26-IgG construct were still tolerogenic. Importantly, anti-CTLA-4 injections reversed tolerance in primed, but not in naive, recipients of transduced LPS blasts. These data emphasize the importance of MHC class II presentation, B cell involvement, and CTLA-4 engagement in induction and/or maintenance of tolerance.
El-Amine
M
M
Department of Immunology, American Red Cross, J. Holland Laboratory, Rockville, MD 20855, USA.
Melo
M
M
Kang
Y
Y
Nguyen
H
H
Qian
J
J
Scott
D W
DW
D000069594:Abatacept; D000595:Amino Acid Sequence; D000818:Animals; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000502:physiology; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism*; D060908:CTLA-4 Antigen; D019070:Cell Lineage / Q000235:genetics / Q000276:immunology; D018014:Gene Transfer Techniques; D005822:Genetic Vectors / Q000008:administration & dosage / Q000138:chemical synthesis / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000235:genetics / Q000502:physiology; D007108:Immune Tolerance / Q000235:genetics* / Q000276:immunology; D018796:Immunoconjugates; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000235:genetics*; D007279:Injections, Subcutaneous; D016753:Interleukin-10 / Q000172:deficiency / Q000235:genetics / Q000502:physiology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D010455:Peptides / Q000008:administration & dosage / Q000235:genetics* / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000096:biosynthesis* / Q000276:immunology*; D012190:Retroviridae / Q000235:genetics / Q000276:immunology
D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556707:Ctla4 protein, mouse; D000949:Histocompatibility Antigens Class II; D018796:Immunoconjugates; D007074:Immunoglobulin G; D010455:Peptides; D011993:Recombinant Fusion Proteins; D016753:Interleukin-10; D000069594:Abatacept